

Special Issue

Advances of Personalized Medicine for Gastric Cancer

Message from the Guest Editor

Precision medicine is reshaping the paradigm of cancer treatment, and the management of gastric cancer has also recently moved toward a tailored therapeutic approach. This Special Issue aims to highlight the most recent acquisitions around the molecular and cellular biology of gastric cancer, and it focuses on the most compelling advances in tailoring of systemic therapies in patients affected by this disease. The growing knowledge about the genomic landscape of gastric cancer has paved the way for the development of novel targeted drugs and the identification of relevant predictive factors. Beyond the introduction of anti-HER2 agents more than ten years ago and, more recently, anti-VEGF drugs, the most promising targets include claudin 18.2 and FGFR, but many trials are ongoing. Articles investigating genetic and epigenetic drivers or other significantly altered pathways, as well as preclinical or clinical studies focused on the molecular profiling, are welcome.

Guest Editor

Dr. Valeria Merz

1. Digestive Molecular Clinical Oncology Research Unit, Università degli Studi di Verona, 37134 Verona, Italy
2. Medical Oncology Unit, Santa Chiara Hospital, 38122 Trento, Italy

Deadline for manuscript submissions

closed (15 July 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/115759

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).